Analysts Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target at $97.60

Key Points

• Analysts have assigned LeMaitre Vascular, Inc. (NASDAQ:LMAT) an average rating of "Hold", with three hold ratings and two buy ratings, and a 12-month price target of $97.60.
• The company reported $0.60 EPS for the quarter, surpassing estimates, and experienced a 15% year-over-year revenue growth, reaching $63.15 million.
• LeMaitre Vascular recently announced a quarterly dividend of $0.20 per share, representing an annualized dividend yield of 0.8%, with a payout ratio of 38.83%.

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have been assigned an average rating of "Hold" from the five brokerages that are presently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $97.60.

A number of research firms have recently weighed in on LMAT. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target on the stock in a report on Wednesday, August 6th. Cantor Fitzgerald boosted their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 100,000 shares of the company's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total value of $9,351,000.00. Following the transaction, the chief executive officer owned 1,727,003 shares of the company's stock, valued at approximately $161,492,050.53. This represents a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John A. Roush sold 6,561 shares of the company's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.55, for a total value of $607,220.55. Following the completion of the transaction, the director directly owned 2,916 shares in the company, valued at $269,875.80. This represents a 69.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 120,815 shares of company stock worth $11,280,206 over the last three months. Corporate insiders own 9.50% of the company's stock.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust grew its position in LeMaitre Vascular by 1,913.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 287 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in shares of LeMaitre Vascular during the 1st quarter valued at $26,000. NBC Securities Inc. purchased a new position in shares of LeMaitre Vascular during the 1st quarter valued at $36,000. Geneos Wealth Management Inc. grew its holdings in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock valued at $47,000 after acquiring an additional 398 shares in the last quarter. Finally, EverSource Wealth Advisors LLC purchased a new position in shares of LeMaitre Vascular during the 2nd quarter valued at $47,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Performance

Shares of LMAT traded down $1.94 during mid-day trading on Wednesday, reaching $92.29. 77,956 shares of the company's stock traded hands, compared to its average volume of 170,861. The business's 50-day moving average price is $89.69 and its 200-day moving average price is $86.06. The stock has a market capitalization of $2.09 billion, a P/E ratio of 44.80, a price-to-earnings-growth ratio of 2.42 and a beta of 0.79. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. The company had revenue of $63.15 million for the quarter, compared to analysts' expectations of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The business's revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Equities analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st were issued a $0.20 dividend. The ex-dividend date of this dividend was Thursday, August 21st. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular's dividend payout ratio is currently 38.83%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.